Delcath Systems Investor Relations Material

Delcath Systems, Inc. is a specialty pharmaceutical company focused on the treatment of primary and metastatic liver cancers in the United States and Europe. The Company is, among other, developing proprietary Melphalan Hydrochloride for Injectable Suspension (MHIS), a technology platform used to administer melphalan HCl, a US Food and Drug Administration-approved chemotherapy drug used to treat primary and metastatic liver cancers.